Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in
young children and elderly people. Although the virus was isolated in 1955, an effective RSV …

The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population
underscores the need for broadly active countermeasures. We employed a directed evolution …

Staphylococcus aureus is a major human pathogen associated with high mortality. The
emergence of antibiotic resistance and the inability of antibiotics to counteract bacterial …

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young
children and the elderly. Therapeutic small molecules have been developed that bind the …

Human metapneumovirus (hMPV) is a frequent cause of bronchiolitis in young children. Its
F glycoprotein mediates virus–cell membrane fusion and is the primary target of neutralizing …

Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in
young children, immunocompromised adults, and the elderly. Intervention with small-molecule …

A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive
prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated …

LukGH (LukAB) is a potent leukocidin of Staphylococcus aureus that lyses human
phagocytic cells and is thought to contribute to immune evasion. Unlike the other bi-component …

Bispecific antibodies continue to represent a growth area for antibody therapeutics, with
roughly a third of molecules in clinical development being T-cell engagers that use an anti-CD3 …

The respiratory syncytial virus (RSV) fusion (F) glycoprotein is a major target of neutralizing
antibodies arising from natural infection, and antibodies that specifically bind to the prefusion …